Hims & Hers Health (HIMS) is back in focus as Amazon’s One Medical pushes further into weight management, while fresh data security lawsuits and upcoming FDA weight loss discussions add legal and regulatory questions.

The recent pullback, including a 10.31% 7 day share price return and earlier single day drops related to Amazon’s expansion and data breach lawsuits, sits alongside a 38.16% 30 day share price return and a 153.80% 5 year total shareholder return that highlight long term momentum despite current volatility.

If weight loss and telehealth competition has your attention, it can be useful to compare Hims & Hers with other names in the space through a focused stock screener such as 33 healthcare AI stocks

Hims & Hers now trades around US$27.41, with an intrinsic value estimate pointing to a roughly 55% discount. However, its recent multi year total returns are already very large, so is there real upside left here, or is the market already pricing in future growth?

Most Popular Narrative: 68.2% Undervalued

At around $27.41 per share versus a fair value of $86.09 in the most followed narrative, Hims & Hers is framed as heavily undervalued according to BlackGoat, with that view hinging on its role as a broad healthcare platform rather than a single product story.

Hims & Hers Health isn’t a telehealth gimmick or a GLP-1 hype stock; it’s quietly becoming the top-of-funnel infrastructure layer for healthcare in the United States. It is executing a strategy similar to Amazon, Spotify, and Costco: deliver more value per dollar spent, reinvest scale advantages, and win via customer-centric efficiency.

Curious what kind of revenue run rate, margin profile, and future profit multiple justify that much upside, and how much weight loss and personalization are baked in.

Result: Fair Value of $86.09 (UNDERVALUED)

However, you also have to weigh the legal and regulatory overhang around GLP 1 practices, as well as the intensity of Big Tech and Big Pharma competition.

Another Way To Look At Value

That 55% DCF-style discount sounds appealing, but the current P/E of 48.7x tells a different story. It is higher than the US healthcare industry average of 24.9x, above peer averages of 38x, and above a fair ratio of 45.9x, which points to valuation risk if sentiment cools.

For a closer look at how this ratio compares with history and peers, review the valuation breakdown and where the fair ratio might eventually pull the share price. Then consider how comfortable you are paying up for growth at these levels.See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

The mix of enthusiasm and caution around Hims & Hers is clear. Move quickly to review the underlying data and pressure test your own thesis using the 3 key rewards and 3 important warning signs.

Looking for more investment ideas?

If you stop with just one stock, you risk missing opportunities that better match your goals, risk comfort, and time horizon across different types of companies.

• Hunt for quality at a marked down price by scanning 51 high quality undervalued stocks and see which businesses line up with your return and risk expectations.
• Build a steadier income stream by checking out 13 dividend fortresses that could help anchor your portfolio with higher yielding names.
• Prioritise resilience first by working through 67 resilient stocks with low risk scores and focus on companies that score well on financial strength and risk metrics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.